Get notified when RADX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Immediate Accretion of Us$2.39 Per Ads to New Investors (new) — New investors pay $3.16 per ADS for a net tangible book value of only $0.77, resulting in immediate dilution of $2.39 per ADS.
Radiopharm Theranostics prices $3.16/ADS offering of 1.28M ADSs, raising $3.3M net for clinical programs
Filed July 27, 2026 · ~1 min read
Key Changes
-
high
Offering of 1,281,646 ADSs at $3.16 each, each ADS representing 300 ordinary shares; primary shares total 384,493,800.
The Offering verify on EDGAR → -
high
Net proceeds to the company are approximately $3.3 million after placement agent fees and offering costs.
Use of Proceeds verify on EDGAR → -
high
Proceeds intended for RAD101 Phase 3 readiness, RAD204 dose escalation, RAD202/RAD402/RV01 programs, and strategic partnering.
Use of Proceeds verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (ORCL 10-Q) is open in full — no account needed.
Partner
Trade RADX commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 1, 2026 · How we verify